RT Journal Article SR Electronic T1 Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection JF Evidence Based Medicine JO Evid Based Med FD BMJ Publishing Group Ltd SP 143 OP 144 DO 10.1136/ebmed-2011-100469 VO 17 IS 5 A1 Mark Danta YR 2012 UL http://ebm.bmj.com/content/17/5/143.abstract AB